Complement Inactivator Proteins

Complement Inactivator Proteins
Accession Number

Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. The complement system is tightly regulated by inactivators that accelerate the decay of intermediates and certain cell surface receptors.

DrugDrug Description
Human C1-esterase inhibitorA C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.
RavulizumabA monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
PegcetacoplanA complement inhibitor indicated in the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Conestat alfaA recombinant C1INH used for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.
Drugs & Drug Targets
Human C1-esterase inhibitorComplement C1r subcomponenttarget
Human C1-esterase inhibitorComplement C1s subcomponenttarget
Human C1-esterase inhibitorPlasma kallikreintarget
Human C1-esterase inhibitorCoagulation factor XIItarget
Human C1-esterase inhibitorProthrombintarget
Human C1-esterase inhibitorCoagulation factor XItarget
Human C1-esterase inhibitorTissue-type plasminogen activatortarget
RavulizumabComplement C5target
PegcetacoplanComplement C3target
Conestat alfaComplement C1r subcomponenttarget
Conestat alfaComplement C1s subcomponenttarget
Conestat alfaPlasma kallikreintarget
Conestat alfaCoagulation factor XIItarget
Conestat alfaProthrombintarget
Conestat alfaCoagulation factor XItarget
Conestat alfaTissue-type plasminogen activatortarget